CDMOs & Contract Manufacturers

Contract development and manufacturing organizations (CDMOs) — and CMOs focused purely on manufacturing — make drug substance and drug product on behalf of the companies that own the marketing authorization. They run GMP manufacturing, commissioning & qualification, and validation for products they did not design, often across many clients and modalities in the same facility. A large and growing share of the world’s medicines is made this way.

A CDMO operates the same GMP the sponsor would: FDA 21 CFR 210/211 for finished product and ICH Q7 for APIs, EU GMP (including Annex 1 for sterile), and ICH Q9/Q10 for risk and the quality system. The defining regulation is EU GMP Chapter 7 (Outsourced Activities), which governs the contract-giver / contract-acceptor relationship, and its FDA analogue — the agency’s guidance on contract manufacturing arrangements for drugs.

Receiving a process from the sponsor and proving it is understood, capable, and validated at the new site — the make-or-break activity for every new product a CDMO takes on.

Cleaning validation, campaign changeover, and cross-contamination control (HBEL-based limits) that keep one client’s product from contaminating another’s in shared facilities.

Risk-based C&Q of facilities, utilities, and equipment (ASTM E2500 / ISPE Vol. 5), and the validated state that every client’s product depends on.

A living contract that assigns every GMP responsibility between contract giver and acceptor — the backbone of a defensible outsourced-manufacturing relationship.

• ›Quality Agreements that are missing, stale, or silent on who owns key decisions
• ›Cross-contamination or mix-ups from weak changeover and segregation controls
• ›Technology transfers that skip process understanding and fail at scale
• ›Client change controls and deviations that fall between the two quality systems

Derived from the 83 standards SPEQ decodes for this sector.